Meeting
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
Authors
Mustafa Özgüroğlu
Istanbul University—Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
Mustafa Özgüroğlu , Benjamin Philip Levy , Hidehito Horinouchi , Jinming Yu , Ellie Grainger , Patrick Hoang Phuong , Daniel Peterson , Michael David Newton , Alexander I. Spira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05211895
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8609)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8609
Abstract #
TPS8609
Poster Bd #
231a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid
Poster
2021 ASCO Annual Meeting
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
First Author: Salma K. Jabbour
Poster
2023 ASCO Annual Meeting
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
First Author: Fabrice Barlesi
Poster
2023 ASCO Annual Meeting
STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.
First Author: Delvys Rodriguez-Abreu